The Rise Of Chinese Biotechs And The Global CRO Question

By Fred Li, Director of Business Development

Chinese biotech is shifting from generic manufacturing toward genuinely novel drug development. This shift was underscored by a Chinese-originated cancer therapy that recently outperformed an established treatment in a major Phase III lung cancer trial. This new phase reflects years of regulatory reform, new funding pathways, returning scientific talent, and an increasingly integrated R&D-to-manufacturing pipeline. As more programs look to compete internationally, sponsor teams face four recurring decisions before their first trial outside their home market: which market to target first, what each regulator requires, how to sequence the program to protect runway, and what the trial will truly cost to run well.

Missing any one of these decisions early tends to compound into delays and budget strain later. Markets with mature, globally accepted regulatory ecosystems can help close this gap, offering faster study startup and data that regulators worldwide already trust. For teams preparing to take a novel therapy beyond their home market, the real challenge isn't proving the science works—it's building a global trial strategy early enough to avoid costly rework, protect timelines, and preserve capital as the program advances.